Summary
In breast cancer patients discontinuing chronic tamoxifen therapy, the serum elimination of metabolites X, Y and E paralleled that of tamoxifen, whereas that of metabolite Z did not. The serum elimination of tamoxifen and metabolites X and B was increased by amino-glutethimide treatment, whereas that of metabolites Z, Y, and E was not.
Article PDF
Avoid common mistakes on your manuscript.
References
Adam HK, Patterson JS, Kemp JV (1980) Studies in the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 64: 761
Al-Turk WA, Stohs SJ (1983) Kinetics of tamoxifen inhibition of aryl-carbon hydroxylase activity of intestinal and hepatic microsomes from male rats. Res Commun Chem Pathol Pharmacol 39: 69
Vos D de, Mould G, Stevenson D (1989) The bioavailability of tamoxifen: new findings and their clinical implications. Curr Ther Res 46: 703
Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127
Golander Y, Sternson LA (1980) Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma. J Chromatogr 181: 41
Guelen PJM, Stevenson D, Briggs RJ, Vos D de (1987) The bioavailability of Tamoplex (tamoxifen): 2. A single dose cross-over study in healthy male volunteers. Methods Find Exp Clin Pharmacol 9: 685
Jordan VC (1982) Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 2: 123
Lien EA, Solheim E, Kvinnsland S, Ueland PM (1988) Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48: 2304
Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49: 2175
Lien EA, Anker G, Lønning PE, Solheim E, Ueland PM (1990) Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 50: 5851
Lien EA, Wester K, Lønning PE, Solheim E, Ueland PM (1991) Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63: 641
Lønning PE (1990) Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. Cancer Chemother Pharmacol 26: 241
Lundgren S, Lønning PE, Aakvaag A, Kvinnsland S (1990) Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 27: 101
Meltzer NM, Stang P, Sternson LA (1984) Influence of tamoxifen and its N-desmethyl and 4-hydroxy metabolites on rat liver microsomal enzymes. Biochem Pharmacol 33: 115
Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS (1991) Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 31: 1450
Patterson JS, Settatree RS, Adam HK, Kemp JV (1980) Serum concentrations of tamoxifen and major metabolite during long-term Nolvadex therapy, correlated with clinical response. In: Mouridsen H, Palshof T (eds) Breast cancer: experimental and clinical aspects. Pergamon, London, p 89
Ruenitz PC, Bagley JR, Pape CW (1984) Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab Dispos 12: 478
Stevenson D, Briggs R, Mould GP (1985) A bioequivalence study of two preparations of tamoxifen after single doses. J Pharm Biomed Anal 4: 191
Stevenson D, Chapman D, Briggs R, Vos D de (1988) Determination of tamoxifen and five metabolites in plasma and urine. J Pharm Biomed Anal 6: 1065
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Vos, D., Slee, P.H.T.J., Stevenson, D. et al. Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer. Cancer Chemother. Pharmacol. 31, 76–78 (1992). https://doi.org/10.1007/BF00695998
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00695998